Home Cart Sign in  
Chemical Structure| 1190932-38-7 Chemical Structure| 1190932-38-7

Structure of COH29
CAS No.: 1190932-38-7

Chemical Structure| 1190932-38-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

COH29 is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity with IC50 value of 8 μM in KB cell.

Synonyms: RNR Inhibitor COH29

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of COH29

CAS No. :1190932-38-7
Formula : C22H16N2O5S
M.W : 420.44
SMILES Code : O=C(NC1=NC(C2=CC=C(O)C(O)=C2)=C(C3=CC=CC=C3)S1)C4=CC=C(O)C(O)=C4
Synonyms :
RNR Inhibitor COH29
MDL No. :MFCD28502212
InChI Key :LGGDLPSXAGQFSG-UHFFFAOYSA-N
Pubchem ID :44253415

Safety of COH29

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of COH29

DNA

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
BT12 4-8-16-20 µM 48 h Inhibition of cell proliferation J Exp Clin Cancer Res. 2023 Dec 20;42(1):346
C4-2 cells 10 μM and 20 μM 24 h Evaluate the inhibitory effect of COH29 on dNTP production, results showed COH29 dose-dependently inhibited dNTP production. Clin Cancer Res. 2019 Jul 15;25(14):4480-4492
Re1P6 3.5-7-14 µM 48 h Inhibition of cell proliferation J Exp Clin Cancer Res. 2023 Dec 20;42(1):346
CHLA266 3.5-7-14 µM 48 h Inhibition of cell proliferation J Exp Clin Cancer Res. 2023 Dec 20;42(1):346
NHDF cells 82 µM 72 h To evaluate the toxicity of COH29 on normal cells, results showed that the IC50 of COH29 for NHDF cells was 82 µM, indicating low toxicity to normal cells. Cancer Res. 2013 Nov 1;73(21):6484-93
MOLT-4 cells 10 µM 4, 8, 24 h To evaluate the effect of COH29 on dNTP pools in MOLT-4 cells, results showed that 10 µM COH29 treatment for 24 h significantly reduced dNTP pools. Cancer Res. 2013 Nov 1;73(21):6484-93
TOV-112D cells 20 µM To evaluate the effect of COH29 on TOV-112D cells, results showed that 20 µM COH29 treatment did not significantly affect RRM2 protein expression. Cancer Res. 2013 Nov 1;73(21):6484-93
KB cells 10 µM 24 h To evaluate the effect of COH29 on RNR activity in KB cells, results showed that 10 µM COH29 treatment for 24 h reduced RNR activity by approximately 50%. Cancer Res. 2013 Nov 1;73(21):6484-93

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOG-SCID mice C4-2 xenograft model Oral gavage 200 mg/kg Twice daily for 3 weeks Evaluate the antitumor effect of COH29 in vivo, results showed COH29 significantly reduced tumor volume and weight. Clin Cancer Res. 2019 Jul 15;25(14):4480-4492
Mice Orthotopic ATRT xenograft model Oral gavage 400 mg/kg Once daily for 3 weeks Suppressed tumor growth and prolonged survival J Exp Clin Cancer Res. 2023 Dec 20;42(1):346
NSG mice MOLT-4 and TOV-112D xenograft models Oral 50 mg/kg, 100 mg/kg, 200 mg/kg, 300 mg/kg, 400 mg/kg Once or twice daily for 28 days To evaluate the inhibitory effect of COH29 on tumor growth, results showed that COH29 significantly inhibited the growth of MOLT-4 and TOV-112D xenografts in a dose-dependent manner. Cancer Res. 2013 Nov 1;73(21):6484-93

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.38mL

0.48mL

0.24mL

11.89mL

2.38mL

1.19mL

23.78mL

4.76mL

2.38mL

References

 

Historical Records

Categories